{"pmid":32224277,"title":"COVID-19 and Immunomodulator/Immunosuppressant Use in Dermatology.","text":["COVID-19 and Immunomodulator/Immunosuppressant Use in Dermatology.","J Am Acad Dermatol","Price, Kyla N","Frew, John W","Hsiao, Jennifer L","Shi, Vivian Y","32224277"],"journal":"J Am Acad Dermatol","authors":["Price, Kyla N","Frew, John W","Hsiao, Jennifer L","Shi, Vivian Y"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32224277","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.jaad.2020.03.046","keywords":["COVID-19","biologics","coronavirus","immunomodulators","immunosuppressants","small molecules","viral immune response"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662819280308142080,"score":7.334329,"similar":[{"pmid":32219857,"title":"Advice regarding COVID-19 and use of immunomodulators, in patients with severe dermatological diseases.","text":["Advice regarding COVID-19 and use of immunomodulators, in patients with severe dermatological diseases.","Coronavirus disease 2019 (COVID-19) is the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as named by the International Committee on Taxonomy of Viruses (ICTV). There is very limited evidence base to formulate specific advice for dermatology patients on immunomodulators with regards to COVID-19. The following is based on expert opinion, taking into account known risks of influenza (a negative sense single-stranded RNA virus) and other, positive-sense single-stranded, RNA virus infections (such as SARS, MERS, and the common cold). An Australia/New Zealand consensus document is in development.","Australas J Dermatol","Rademaker, Mariu","Baker, Christopher","Foley, Peter","Sullivan, John","Wang, Charlie","32219857"],"abstract":["Coronavirus disease 2019 (COVID-19) is the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as named by the International Committee on Taxonomy of Viruses (ICTV). There is very limited evidence base to formulate specific advice for dermatology patients on immunomodulators with regards to COVID-19. The following is based on expert opinion, taking into account known risks of influenza (a negative sense single-stranded RNA virus) and other, positive-sense single-stranded, RNA virus infections (such as SARS, MERS, and the common cold). An Australia/New Zealand consensus document is in development."],"journal":"Australas J Dermatol","authors":["Rademaker, Mariu","Baker, Christopher","Foley, Peter","Sullivan, John","Wang, Charlie"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32219857","week":"202013|Mar 23 - Mar 29","doi":"10.1111/ajd.13295","source":"PubMed","locations":["Australia","New Zealand"],"countries":["Australia","New Zealand"],"countries_codes":["AUS|Australia","NZL|New Zealand"],"topics":["Treatment"],"weight":1,"_version_":1662540582057148416,"score":88.81218}]}